Relmada And REL-1017: Intriguing Underlying Efficacy In MDD Ahead Of Eventful 2024
Shutter2U/iStock via Getty Images Intro Relmada Therapeutics (NASDAQ:RLMD) is advancing its NMDA antagonist, REL-1017 (esmethadone), as a novel antidepressant for ...